State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia

Djavan, Bob; Chapple, Christopher R.; Milani, Shirin; Marberger, Michael

doi:10.1016/j.urology.2004.07.031

Cited by 183 publications

(138 citation statements)

References 46 publications

Supporting

Mentioning

121

Contrasting

Unclassified

Order By: Relevance

“…[1][2][3][4][5] Recent studies have highlighted the influence of a1-blockers on ejaculatory function. [6][7][8][9][10] A loss of seminal emission has been recently postulated as one of the mechanisms of abnormal ejaculation.…”

Section: Introductionmentioning

confidence: 99%

Orgasm is preserved regardless of ejaculatory dysfunction with selective α1A-blocker administration

et al. 2009

View full text Add to dashboard Cite

We evaluated whether ejaculatory dysfunction induced with a selective a1A-blocker influenced orgasm. Fifteen healthy male volunteers took silodosin or a placebo in a randomized, double-blind crossover design. We investigated the ejaculatory volume before and after administration of the agents. After each ejaculation, participants self-reported the answers to an original questionnaire, which was about discomfort on ejaculation, orgasm and satisfaction with the discomforting ejaculation. All participants on silodosin had a complete lack of seminal emission and expulsion. All participants felt orgasm in spite of a complete lack of seminal emission. Of the 15, 12 (80%) who had a somewhat uncomfortable feeling during orgasm were dissatisfied with this feeling, although 9 of the 12 reported that its degree was mild. Orgasm is preserved regardless of the loss of seminal emission with silodosin administration. Although most participants reported mild discomfort during orgasm, they were greatly dissatisfied with the loss of seminal emission.

show abstract

Section: Introductionmentioning

confidence: 99%

Orgasm is preserved regardless of ejaculatory dysfunction with selective α1A-blocker administration

et al. 2009

View full text Add to dashboard Cite

show abstract

“…2 Radical, abdominal with lymph toilet 5-604. 3 Radical, perineal with lymph toilet 5-604. 9 Unspecified prostatic surgery 5-605…”

Section: Discussionmentioning

confidence: 99%

“…Clinical trials have shown that 5-alpha-reductase inhibitors (5-ARIs) and alpha-blockers are effective in reducing LUTS suggestive of BPH and improving urinary flow [3]. Alpha-blockers reduce smooth muscle tone in the bladder neck and the prostate, while 5-ARIs inhibit the conversion of dihydotestosteron to testosterone and, as a result, shrink the prostate.…”

Section: Introductionmentioning

confidence: 99%

Drug Treatment of Benign Prostatic Hyperplasia and Hospital Admission for BPH-Related Surgery

et al. 2003

View full text Add to dashboard Cite

Objective: To investigate whether there is a difference in the risk of progressing to BPH-related prostatic surgery between patients using alpha-blockers and patients using the 5-alpha-reductase inhibitors (5-ARIs).Methods: A population-based cohort study was conducted, using data from the PHARMO Record Linkage System. We identified 5671 patients ( 50 years old, no history of using both alpha-blockers and 5-ARIs, more than one year of database history prior to the first date of BPH drug-dispensing), who filled at least one prescription for either alpha-blockers (alfuzosin, tamsulosin, terazosin) or 5-ARIs (finasteride). The incidence of BPH-related surgery was compared between patients treated with alpha-blockers and patients treated with 5-ARIs. Results: The cumulative incidence of BPH-related prostatic surgery was 15.2% and mainly involved transurethral resection of the prostate (TURP) (13.4%). Patients using alpha-blockers had a significantly increased risk of BPHrelated prostatic surgery compared to patients using 5-ARIs, which remained after adjusting for age, calendar time, type of prescriber and chronic disease score (adjusted HR: 1.52, 95% CI: 1.24-1.88). The difference between alphablockers and 5-ARIs was sustained after stratification of time period (<1995, 1995) and exclusion of patients with prostatic surgery within one month of treatment initiation. Conclusions: It is concluded that alpha-blocker treated patients had a higher risk of BPH-related surgery compared to 5-ARI treated patients. Additional research on the long-term outcomes and risk factors for the natural progression of BPH is necessary to identify the optimal medical treatment for BPH patients according to their baseline characteristics. #

show abstract

“…Thus, systemic treatment with α-1 AR inhibitors (alfuzosin, doxazosin, tamsulosin and terazosin) has been a successful therapy of LUTS including benign prostatic hyperplasia, but the same treatment may cause some degree of IFIS during cataract surgery. Due to a better cardio-vascular profile tamsulosin and alfuzosin seems to be better tolerated than doxazosin and terazosin (Djavan et al 2004). However, tamsulosin also has a very high affinity for the α-1a and α-1d ARs in the smooth muscular tissue of the iris.…”

Section: Etiologymentioning

confidence: 99%

Management of Intraocular Floppy Iris Syndrome (IFIS) in Cataract Surgery

Storr‐Paulsen¹

2013

Cataract Surgery

View full text Add to dashboard Cite

State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia

Cited by 183 publications

References 46 publications

Orgasm is preserved regardless of ejaculatory dysfunction with selective α1A-blocker administration

Orgasm is preserved regardless of ejaculatory dysfunction with selective α1A-blocker administration

Drug Treatment of Benign Prostatic Hyperplasia and Hospital Admission for BPH-Related Surgery

Management of Intraocular Floppy Iris Syndrome (IFIS) in Cataract Surgery

Contact Info

Product

Resources

About